Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

Cancer

Volumn 120, Issue 2, 2014, Pages 229-237

  Tsuchiya, Kaoru ^a   Asahina, Yasuhiro ^b   Matsuda, Shuya ^a   Muraoka, Masaru ^a   Nakata, Toru ^a   Suzuki, Yuichiro ^a   Tamaki, Nobuharu ^a   Yasui, Yutaka ^a   Suzuki, Shoko ^a   Hosokawa, Takanori ^a   Nishimura, Takashi ^a   Ueda, Ken ^a   Kuzuya, Teiji ^a   Nakanishi, Hiroyuki ^a   Itakura, Jun ^a   Takahashi, Yuka ^a   Kurosaki, Masayuki ^a   Enomoto, Nobuyuki ^c   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

antiangiogenic therapy; biomarker; hepatocellular carcinoma; prognosis; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL SKIN REACTION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; TREATMENT RESPONSE;

EID: 84891887901     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28384     Document Type: Article

References (30)

1. World Health Organization, International Agency for Research on Cancer (IARC);, Boyle P, Levin B, eds. World Cancer Report 2008. Lyon, France: IARC Press; 2008.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.
3. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
5. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J,. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18: 2290-3000.
6. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
7. Shao YY, Lin ZZ, Hsu C, Shen CH, Cheng AL,. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116: 4590-4596.
8. Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011; 81: 251-258.
9. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012; 57: 101-107.
10. Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012; 56: 1080-1088.
11. Hora C, Romanque P, Dufour JF,. Effect of sorafenib on murine liver regeneration. Hepatology. 2011; 53: 577-586.
12. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Makuuchi M,. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011; 29: 339-364.
13. Bruix J, Sherman M,; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
14. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998; 27: 1554-1562.
15. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M,. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998; 28: 68-77.
16. Yoshiji H, Kuriyama S, Yoshii J, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 2002; 35: 834-842.
17. Tamesa T, Iizuka N, Mori N, et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology. 2009; 56: 1122-1126.
18. Hu J, Xu Y, Shen ZZ, et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res. 2009; 135: 1359-1367.
19. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST,. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol. 2007; 14: 1835-1845.
20. Schoenleber SJ, Kurtz DM, Talwalkar JA, Rober LR, Gores GJ,. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systemic review and meta-analysis. Br J Cancer. 2009; 100: 1385-1392.
21. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA,. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2009; 115: 4895-4906.
22. Kaseb A, Hassan M, Lin E, Xiao L, Kumar V, Morris J,. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011; 117: 2478-2488.
23. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26: 2992-2998.
24. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X,. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004; 10: 2878-2882.
25. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H,. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol. 1999; 14: 1087-1090.
26. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF and poor prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008; 99: 2037-2044.
27. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S,. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut. 2001; 48: 87-96.
28. Zhu AX, Ancukiewicz M, Duda DG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013; 19: 1557-1566.
29. Jayson GC, de Haas S, Delmar P, et al. Evaluation of plasma VEGF-A as a potential predictive pan-tumour biomarker for bevacizumab. Abstract 804. Paper presented at: 2011 European Multidisciplinary Cancer Congress; Stockholm, Sweden; September 23-27, 2011.
30. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012; 118: 147-156.